Xoma to Pay $1M to LadRx as Rare Disease Therapy Undergoes FDA Review

Seeking AlphaJan 12 20:44

Xoma To Make $1 Mln Milestone Payment To LadRx After FDA Accepts Zevra's NDA For Arimoclomol

RTTNewsJan 12 05:37

LadRx Issues 2024 Update to Shareholders

FDA Acceptance of Arimoclomol Triggers $1 Million Payment LadRx Corporation (OTCQB:LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer

BusinesswireJan 9 21:00

XOMA Acquires Drug Rights From LadRx for $5M

Seeking AlphaJun 23, 2023 00:23

XOMA Acquires Royalty, Milestone Rights for Two Assets From LadRx

XOMA (XOMA) said Thursday it has acquired the royalty and milestone rights for two assets from LadRx for $5 million. The assets are arimoclomol, an investigational treatment for neurogenerative disord

MT NewswiresJun 22, 2023 22:03

Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 Oncology, Respectively

Xoma Has Acquired The Royalty And Milestone Rights Associated With Two Assets From LadRx, Including Arimoclomol And Aldoxorubicin, For $5M, For Orphan Disease Niemann-pick Disease Type C And Phase 2 O

BenzingaJun 22, 2023 19:39